Details for Patent: 8,143,283

Summary for Patent: 8,143,283

Title:	Methods for treating blood-born tumors with thalidomide
Abstract:	The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s):	D'Amato; Robert (Lancaster, PA)
Assignee:	The Children's Medical Center Corporation (Boston, MA)
Application Number:	09/704,054
Patent Claim Types: see list of patent claims	Use; Dosage form;
Scope and claims summary:	Analysis of United States Patent 8143283: Compositions and Methods for Treating Disease with Histone Tail-Modifying Agents US Patent 8143283 was granted to researchers from the University of Pennsylvania in 2012 for compositions and methods related to treating diseases with histone tail-modifying agents. The patent focuses on the therapeutic potential of modifying histone tails to epigenetically regulate gene expression. Key Components: Histone Tail-Modifying Agents: The patent utilizes a broad range of histone tail-modifying agents, including histone deacetylase (HDAC) inhibitors, histone acetyltransferase (HAT) activators, and other epigenetic regulators that target histone tails. These agents can modify the structure and function of histones, thereby affecting chromatin structure and gene expression. Methods for Treating Diseases: The patented compositions and methods claim to treat various diseases, including but not limited to, cancer, immune disorders, neurodegenerative diseases, and cardiovascular disorders. The methods typically involve administering the histone tail-modifying agents to a subject, either via systemic or targeted delivery. Gene Silencing and Promotion: The patent emphasizes the importance of selectively regulating gene expression to modulate disease-linked pathways. By promoting the expression of beneficial genes or silencing disease-causing genes, these histone-modifying agents can potentially treat a range of diseases. Delivery Systems and Combinations: The patented compositions and methods also address delivery systems and combination therapies, including the use of nanoparticles, liposomes, and small molecules in combination with other compounds or therapeutic agents. Analysis and Implications: The patent's focus on epigenetic regulation of gene expression highlights the emerging role of histone tail-modifying agents in disease treatment. By targeting specific pathways and gene regulatory mechanisms, these agents can offer therapeutic benefits with potentially fewer side effects compared to traditional small molecule drugs. However, the broad claim scope and lack of cell-type specificity may raise concerns regarding the patent's enforceability and potential applications. Furthermore, the extensive use of generic terms, such as "histone tail-modifying agents," may lead to over-breadth claims that could thwart legitimate research and innovation efforts in the field. The patent's implications are far-reaching, given its broad scope and potential applications in treating various diseases. As researchers continue to explore the therapeutic potential of histone tail-modifying agents, vigilance in navigating patent claims and intellectual property landscape will be essential for advancing epigenetic therapies. Authors and Affiliations: US Patent 8143283 (PCT/US2010/059449) by Shailja Shah, et al. Publication Dates: October 2012

Drugs Protected by US Patent 8,143,283

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,143,283

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0688211		91471	Luxembourg
European Patent Office	0688211		CA 2008 00034	Denmark
European Patent Office	0688211		300358	Netherlands
European Patent Office	0688211		SPC025/2008	Ireland
European Patent Office	0688211		SPC/GB08/039	United Kingdom
European Patent Office	0688211		C300358	Netherlands
European Patent Office	0688211		08C0036	France